Form 4: Tourmaline Bio Director Sapna Srivastava Granted 16,800 Stock Options

Tourmaline Bio, Inc. Director Sapna Srivastava has been granted 16,800 stock options with an exercise price of $18.73, aligning her incentives with future company performance.

Summary

• Sapna Srivastava, a Director of Tourmaline Bio, Inc. (TRML), acquired 16,800 stock options on June 4, 2025.
• The stock options have an exercise price of $18.73 per share.
• The options are set to vest 100% on the earlier of June 4, 2026 (the one-year anniversary of the transaction date) or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to Ms. Srivastava's continued service.
• These options will expire on June 4, 2035.
• Following this transaction, Ms. Srivastava beneficially owns 16,800 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director is generally a positive indicator as it aligns their interests with shareholders, suggesting confidence in future growth. However, it is a routine compensation event rather than a significant strategic announcement.

Positives

• The grant of stock options to a director aligns their financial interests directly with the long-term performance and appreciation of Tourmaline Bio's common stock.
• The vesting schedule encourages the director's continued service and commitment to the company's strategic objectives.

Risks

• The value of the granted stock options is contingent on Tourmaline Bio's common stock price exceeding the exercise price of $18.73; if the stock price remains below this threshold, the options may expire worthless.
• Vesting of the options is subject to the director's continued service, meaning the options could be forfeited if her service terminates before the vesting date.

Future Outlook

The grant of stock options to a director is a forward-looking incentive, aligning the director's future financial success with the company's stock performance, thereby encouraging strategic decisions aimed at increasing shareholder value over the long term.

Industry Context

This transaction represents a standard practice of equity compensation for directors in publicly traded companies, particularly within the biotechnology sector. Such grants are designed to attract and retain qualified board members by linking their compensation to the company's stock performance, a common mechanism for aligning insider interests with those of shareholders.

Comparison to Industry Standards

• Granting stock options to directors is a widespread compensation practice across various industries, including biotechnology, to incentivize long-term performance and commitment.
• The vesting schedule, typically over one to four years, is consistent with industry norms for equity compensation, ensuring continued service and alignment of interests.
• The exercise price being set at the market price on the grant date (implied by the nature of the option grant) is a standard approach for incentive stock options or non-qualified stock options.

Stakeholder Impact

• **Shareholders:** The grant aligns the director's financial incentives with shareholder value creation, potentially leading to decisions that benefit stock price appreciation.
• **Employees:** This transaction is part of the company's overall compensation strategy, which may influence employee morale and retention if similar equity grants are part of broader compensation plans.

Next Steps

• Monitoring the future vesting of these options and any subsequent exercise or sale transactions by the reporting person.
• Observing Tourmaline Bio's stock price performance relative to the $18.73 exercise price to assess the potential value of these options.

Key Dates

Keywords

Tourmaline Bio, TRML, Form 4, Insider Transaction, Stock Options, Director Compensation, Equity Grant, Sapna Srivastava